News

Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
The antibody treatment could compete with Sanofi’s Dupixent and Eli Lilly’s Ebgylss, while offering the potential for less ...
Apogee Therapeutics’ anti-IL-13 antibody has been tied to a 71% reduction in eczema severity after 16 weeks, hitting the main ...
Apogee Therapeutics said its antibody treatment alleviated signs and symptoms of atopic dermatitis far more than a placebo — ...
Apogee Therapeutics Inc. plans to enter a crowded atopic dermatitis market with established drugs, such as Dupixent (dupilumab, Regeneron Pharmaceuticals Inc. and Sanofi SA) and Ebglyss ...
The atopic dermatitis therapeutics market is poised for steady growth, with revenues projected to rise from USD 15.43 billion in 2024 to USD 29.5 billion by 2033. This reflects a compound annual ...
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the 10 Best Value Stocks to Buy According to Billionaires. Regeneron ...
In this video, Robert J. Smith, MD, discusses the many treatment options available to patients with atopic dermatitis.
When somebody's coming in that has a known diagnosis of atopic dermatitis or eczema and things are really revved up still, if ...
Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.
Rezpeg's promising Phase 2b data makes Nektar Therapeutics a strong contender in the AD market. Click here to read an analysis of NKTR stock now.
Regeneron's Dupixent leads growth as Eylea sales decline and valuation is attractive, but growth is delayed by 2-3 years. Learn more on REGN stock here.